Several mammalian DNA viruses (e.g., herpesviruses and adenoviruses) and certain retroviruses (e.g., human T-lymphotropic virus types I and II, spumaviruses, and lentiviruses) encode proteins which regulate viral transcription and provide temporal control of viral gene expression and replication (8, 20, 32, 42) . Mechanisms by which these viral regulatory genes, designated transactivators, stimulate gene expression are poorly understood. Viral transactivator proteins may not bind directly to the promoters whose expression they stimulate (for a review, see reference 15) . Thus, the presence or absence of specific cellular proteins appears to govern the ability of viral transactivators to function. Other reports have noted the effects of host cells on the abilities of viral transactivators to stimulate expression from the human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR) (17, 54) . This has important clinical implications, because the level of required cellular proteins may determine whether a viral infection is productive or abortive in specific cell types and whether a virus is maintained in a latent state.
The virally encoded TAT protein of HIV-1 stimulates HIV-1 gene expression and is essential for viral replication (13, 14) . TAT functions through the trans-acting responsive element (TAR) located downstream of the start site of transcription between +19 and +42 (relative to the cap site at +1 in the HIV-1 LTR) (33, 46, 48) . Despite extensive studies, the mechanism by which TAT increases gene expression still requires resolution. TAT appears to increase the frequency of transcription initiation (28, 43) by binding to TAR RNA and interacting with components of the transcription complex (5, 49) . By a mechanism that may be intrinsically related to transcription initiation, TAT eliminates a block to transcription elongation on the HIV-1 LTR (25, 28, 48) . Its effects may also be mediated at a posttranscriptional level (6, 7, 11, 39, 45, 54) . Whatever the precise mechanism, TAT regulates HIV-1 gene expression by interacting with a target element in the HIV-1 LTR; this interaction may involve cellular proteins (35, 54) . * Corresponding author.
The immediate-early (IE) gene of cytomegalovirus (CMV) encodes multiple proteins which are translation products of differentially spliced mRNAs (22, 52) . Although the functions of IE are not fully understood, these regulatory gene products are capable of stimulating expression from other CMV promoters, as well as autoregulating their expression (9, 41) . The most abundant IE protein (IE1) increases expression from the major IE promoter (9) , while the IE2 gene product both negatively regulates IE expression and positively regulates heterologous promoters (12, 22, 41) . IEl by itself does not transactivate heterologous promoters but appears to have small synergistic effects on the transactivation capacities of IE2 (22) . The mechanism by which CMV IE transactivates promoters is not known. For the HIV-1 promoter, CMV IE probably functions by increasing the frequency of transcription initiation through interactions within a region of the HIV-1 LTR encompassing the cap site; sequences in the LTR between -6 and +20 (relative to the start site of transcription at + (24) . We used 10 to 40 ,ug of total RNA for RNase protection.
[32P]-labeled RNA probes were synthesized as described by Melton et al. (31) . The protocol for RNase protection has already been described (3, 48) . (22) and was constructed by substituting the CMV IE coding region for the TAT-encoding region of pUCSVTAT (see Materials and Methods). pUCHIVLTR/ CAT was cotransfected with either pUCSVTAT or pUCS VIE into MRC-5, L929 (transformed murine fibroblast), HTB-17 (human glioblastoma, also known as U-373 MG), and HeLaS3 (human cervical carcinoma) cell cultures which were harvested at 44 h for CAT activity. The results are presented in Table 1 .
RESULTS
Both pUCSVTAT and pUCSVIE increased expression from pUCHIVLTR/CAT in all four cell types, compared with transfection with pUCHIVLTR/CAT alone. However, the relative abilities of pUCSVTAT and pUCSVIE to transactivate the HIV-1 LTR varied dramatically among these cell types. In MRC-5 cell cultures, pUCSVIE increased CAT expression over 66-fold, compared with an 11.5-fold increase in CAT activity with pUCSVTAT ( tion was 0.7, while in cultures transfected by CaPO4, the ratio was 0.4. Similarly, in HeLa cultures transfected by DEAE dextran, the ratio was 0.03, while in CaPO4 transfected cultures, the ratio was 0.01. Similar ratios for pUCS VIE-to-pUCSVTAT transactivation were observed with two methods of transfection; thus, the results (Tables 1 and 2) were not a reflection of the method used to facilitate entry of transfecting DNA into cells. Furthermore, the ratios were independent of the time when the cells were harvested posttransfection and the amount of DNA used in the transfection (data not shown).
The relatively high level of transactivation of the HIV-1 LTR by TAT in murine L929 cells is at variance with reports indicating that rodent cells are insufficient in the ability to support TAT-mediated transactivation of the HIV-1 LTR, including subclones of mouse L cells (21, 37) . In our study, DEAE-mediated transfection of L929 cells resulted in higher levels of CAT activity than did CaPO4-mediated transfection ( Table 2 ). We do not know whether DEAE-mediated transfection was responsible for the higher levels of transactivation by TAT than those previously reported (21, 37) . To avoid the possibility of contamination of our L929 cells with human cells, we assayed a second lot of L929 cells obtained directly from the American Type Culture Collection. These cells were just as fully capable as our older stock of L929 cells of supporting a high level of transactivation of the HIV-1 LTR; the ratio of transactivation by CMV IE relative to TAT was 0.4 (data not shown).
The ratios of pUCSVIE-to-pUCSVTAT transactivation were consistent between experiments. This is illustrated for MRC-5, L929, HTB-17, and HeLa cell cultures by comparing the results of both Tables 1 and 2 , which represent independent experiments with each cell type. Although the actual levels of CAT enzymatic activity with each transactivator varied between the two experiments represented (in Tables 1 and 2 ), the ratios of pUCSVIE-to-pUCSVTAT transactivation remained relatively constant (5.8 and 8.8 for MRC-5; 0.7 and 0.7 for L929; 0.2 and 0.2 for HTB-17; 0.01 and 0.03 for HeLa). Thus, the ratio of pUCSVIE-to-pUCS VTAT transactivation was characteristic for each cell type.
Differences in the ratios were not related to cell tropism for CMV infection and replication. MRC-5 and Hs68 cells (human foreskin fibroblast) were productively infected with CMV (data not shown) and showed ratios of 8.8 and 4.3, respectively (Table 2) . Similarly, HTB-17 cells were also infected by CMV (data not shown) yet had a 10-fold lower ratio of 0.2. CMV does not productively infect NIH 3T3, L929, or HeLa cell cultures (ratios of 25.1, 0.7, and 0.03, respectively) (26 and data not shown). Thus, permissiveness for CMV infection was not related to the abilities of pUCS VIE and pUCSVTAT to transactivate the HIV-1 LTR.
A general correlation noted from the results in Tables 1  and 2 was a higher ratio of CMV IE-to-TAT transactivation in cell types that had a finite life span in culture, including MRC-5, Hs68, and Bc-1 (murine mammary epithelium) cells, and in nontransformed cells (e.g., NIH 3T3 cells). MRC-5, Hs68, and Bc-1 cell strains, derived from primary cells, grew in monolayers, and all had CMV IE-to-TAT ratios of approximately 5 to 1. NIH 3T3 cells, immortal but nontransformed, had the highest ratio at 25 to 1. With two exceptions, the other cell lines assayed were transformed lines; each had a CMV IE-to-TAT ratio less than or equal to approximately 1. Transfections into primary PBL are an interesting exception to the correlation described above. The ratios of CMV IE-to-TAT transactivation in HuPBL and RhPBL were 0.2 and 0.08, respectively. After isolation from the donor, the PBL were cultured for 5 days under mitogenic and T-cell activation conditions, which were optimal for growth stimulation. Preliminary evidence indicates that the ratio of transactivation may change under different growth conditions for PBL, particularly when the cells are cultured under less stimulatory conditions (data not shown).
CMV IE proteins in transfected cell cultures. The preceding data indicate that the abilities of CMV IE and HIV-1 TAT to transactivate the HIV-1 LTR varied between different cell types. Although expression of both TAT and CMV IE was driven by the SV40 early promoter, we examined whether the CMV IE-to-TAT transactivation ratio differences between cell types were due to differences in the synthesis and localization of the transactivator proteins. We focused our attention on CMV IE.
The CMV IE gene encodes multiple proteins from a differentially spliced precursor transcript (22, 52 (22, 50, 51) . We noted an abundant 43-kDa protein in cultures which appeared within 3 h of reversal of the cycloheximide block. It is not certain whether this represents the previously characterized IEi protein (50) , albeit in much greater levels than reported, or another, uncharacterized, CMV IE protein.
Two features were observed for radiolabeled CMV IE proteins in cell cultures transfected with pUCSVIE. The first was that the same CMV IE proteins were observed in all four cell types as in CMV-infected MRC-5 cells (Fig. 1, lanes 1, 4,  7, 8, 10, and 11 ). These proteins were not detected in the negative controls (Fig. 1, lanes 2, 3, 5, 6 , and 9). The two predominant bands in the transfected cell cultures were the 66-and 43-kDa proteins. The second feature was the variation between cultures in the relative levels of the different proteins, particularly the 66-and 43-kDa species. In MRC-5 cells (Fig. 1, lane 10) , there was a much greater amount of the 66-kDa protein than the 43-kDa protein. In HeLa cells (Fig. 1, lane 2 ), there was a greater level of the 66-kDa protein, although the difference from that of the 43-kDa protein was not as great as in MRC-5 cells. In L929 (Fig. 1,  lane 5 ) and HTB-17 ( Fig. 1, lanes 7 and 8) cells, the 43-kDa species predominated over the 66-kDa protein. The differences between the relative levels of these two proteins were most likely a function of the time of harvesting after transfection. This is illustrated for HTB-17 cells which were harvested at 24 (Fig. 1, lane 7) and at 48 (Fig. 1, lane 8) tion. While the cultures were harvested at 48 h posttransfection, different cell types responded differently to electroporation in terms of resumption of cell growth (data not shown). We believe that any differences in the levels of the different CMV IE proteins were a reflection of the electroporation process and not due to fundamental differences between cell types in the expression of the multiple CMV IE proteins. In addition, the pattern of temporal expression of the 43-kDa protein, relative to the 66-kDa species, indicates that the 43-kDa protein was not a degradation product.
We also used MAb 810 to determine the intracellular location of CMV IE. In all four cell types (MRC-5, L929, HTB-17, and HeLa), IE proteins recognized by MAb 810 were localized by immunohistochemistry to the nuclei of transfected cells (data not shown).
HIV-1 transcripts in transfected cell cultures. The experiments described above measured transactivation of the HIV-1 LTR by CMV IE and TAT at the protein level (i.e., increases in CAT activity). We assessed the response of the HIV-1 LTR to these transactivators at the RNA level by measuring steady-state levels of LTR transcripts. Cultures of MRC-5, HTB-17, and HeLa cells were transfected with no DNA, pUCHIVLTR/CAT, pUCHIVLTRICAT plus pUCS VTAT (MRC-5 and HTB-17 only), or pUCHIVLTRICAT plus pUCSVIE. Total RNA was isolated and analyzed by RNase protection by using an RNA probe complementary to nucleotides -138 to +82 of the antisense strand of the HIV-1 LTR. In cells transfected with no DNA, there were no protected transcripts (Fig. 2, lanes 1, 5, and 11) . Transfection with pUCHIVLTR/CAT resulted in low levels of transcripts predominantly 55 nucleotides (nt) long and little full-length transcript, which in this experiment corresponded to 82 nt (Fig. 2, lanes 2, 6, and 9) . The short transcripts represent incompletely elongated transcripts (25, 48 Cotransfection with pUCSVTAT (Fig. 2, lanes 3 and 7) resulted in transcriptional elongation in both MRC-5 and HTB-17 cells, resulting in predominantly full-length transcripts. This was also observed in HeLa cells (data not shown). The full-length transcripts appeared as a doublet, most likely due to secondary structure. Cotransfection of pUCHIVLTR/CAT with pUCSVIE resulted in dramatically different patterns of protected transcripts. In MRC-5 cells (Fig. 2, lane 4) , there were large increases in steady-state levels of both full-length and short transcripts, with greater levels of the former. In HTB-17 cells (Fig. 2, lane 8) , there were also large increases in steady-state levels of short and full-length species, with essentially equimolar amounts of each. The results of MRC-5 and HTB-17 were similar to those previously reported (3, 4) . Strikingly, in HeLa cells (Fig. 2, lane 10) , cotransfection with pUCSVIE resulted in large increases in short transcripts only, with only a small increase in the full-length transcript. We found that equal amounts of RNA from the different HeLa transfectants were utilized for RNase protection by analyzing steady-state levels of the cellular y-actin transcript (data not shown). In HeLa cells, the inability of pUCSVIE to increase CAT expression from pUCHIVLTR/CAT occurred at the level of transcription elongation.
We noted a curious aspect to transactivation by pUCS VTAT in these analyses. In some cases, there was no correlation between the level of CAT activity upon cotransfection with pUCSVTAT and the steady-state level of the full-length transcript. This is illustrated for transfections of HTB-17 cell cultures (Fig. 2, lanes 5 to 8) . Without exception, cotransfections with TAT into HTB-17 cells resulted in larger increases in CAT activity than did cotransfection with CMV IE (Tables 1 and 2 steady-state levels of RNA, there were greater levels of the full-length transcript upon cotransfection with CMV IE than with TAT ( Fig. 2) (4) . Although we did not investigate this further, such a result is consistent with a posttranscriptional role for TAT (6, 7, 11, 39, 45) , in addition to a role in transcription initiation and elongation (5, 25, 28, 43, 48, 49) . DISCUSSION Productive viral infection and replication are dependent on several cellular processes, including cell surface receptors, as well as the transcriptional and translational machinery. The success or failure of viral replication, or the maintenance and abrogation of latency, hinges on the presence of critical cellular factors. Differential expression of these cellular proteins could occur in different cell types and, perhaps, at specific stages in the cell growth cycle. We have identified a point in the life cycle of HIV-1, elongation of transcription, which requires host cell factors and proceeds with various efficiencies, depending on the cell type.
This report analyzes the responses of the HIV-1 LTR to its autologous transactivator, TAT, and a heterologous transactivator, CMV IE. Expression of both TAT and CMV IE was under transcriptional control of the same promoter, the SV40 early promoter, to eliminate variability that might occur in different cell types. When transient expression assays were performed with multiple cell types, dramatic variations in the abilities of the two transactivators to increase expression directed by the HIV-1 LTR were observed (Tables 1 and 2 ). The variation in transactivation between cell types, measured as changes in the level of transactivation of the HIV-1 LTR by CMV IE relative to the level of transactivation by TAT, was almost 1,000-fold ( Table 2) .
The ratio of CMV IE-to-TAT transactivation of the HIV-1 LTR has been remarkably constant between experiments, despite the observation that the absolute CAT activities used to calculate the ratio varied (Tables 1 and 2) (1, 3, 4) . Even though the SV40 promoter was used to drive expression of both CMV IE and HIV-1 TAT, potential posttranscriptional mechanisms could lead to differential expression of CMV IE in various cell types. After transfection of pUCSVIE into MRC-5, L929, HTB-17, and HeLa cell cultures, we detected CMV IE expression by immunohistochemistry in nuclei of all four cell types (data not shown). Thus, the localizations of CMV IE were similar in all of the cell types. By radioimmunoprecipitation of CMV IE, we detected no overt differences among these four cell types in the pattern of expression of the multiple IE proteins (Fig. 1) . It is possible that there are critical minor proteins that either were not recognized by the antibody to CMV IE or were below the level of detection. In addition, there may be cell-specific posttranslational modifications (e.g., phosphorylation) that we would not have detected.
The region of the HIV-1 LTR between -6 and +20 (relative to the cap site at +1) is involved in mediating responsiveness to transactivation by CMV IE in both MRC-5 cells (3) and L929 cells (4) . Thus, CMV IE transactivates the HIV-1 LTR through the same cis-acting element in different cell types from several species. Data on patterns of RNA and CAT transactivation are consistent with a model in which CMV IE functions to increase the frequency of transcription initiation. If CMV IE functions to increase the frequency of transcription initiation (an assumption that requires direct examination), the mechanism of the block to elongation is independent of the mechanism of initiation. In the presence of CMV IE in transfected HeLa cell cultures, there was a large increase in the steady-state levels of the short 55-nucleotide transcript (Fig. 2, lane 10 ) compared with cells transfected with HIVLTR/CAT alone (Fig. 2, lane  9) . The block to elongation is dominant over the increase in the frequency of initiation, such that in the absence of TAT function in HeLa cells, most of the transcription complexes on the HIV-1 LTR fail to elongate fully and produce a full-length message. In MRC-5 cells, the block to elongation is not as efficient as in HeLa cells; thus, most initiated transcription complexes are capable of producing full-length transcripts. In HTB-17, elongation is blocked at a level intermediate between those observed in HeLa and MRC-5 cells. The ratios of CMV IE-to-TAT transactivation correlate inversely with the efficiency of the block in elongation; the greater the ratio, the less efficient the block to transcription initiation (MRC-5 cells), and the lower the ratio, the more efficient the block to elongation (HeLa cells).
Recent reports have shown that human chromosome 12 encodes a factor necessary for efficient transactivation by TAT in human cell cultures (21, 37) . Furthermore, rodent (hamster and mouse) cells are apparently deficient in this factor and do not support efficient transactivation by TAT.
Our results suggest that inability of TAT to transactivate the HIV-1 LTR is not a function of all rodent cells. In the experiments reported here, TAT was a very strong transactivator in mouse L929 cells (Tables 1 and 2 ). Notably, this was the only rodent cell line in which we observed a high level of transactivation of the HIV-1 LTR by TAT. One issue that requires consideration is whether TAT transactivates the HIV-1 LTR by a bimodal mechanism (5, 6, 7, 11, 25, 28, 39, 43, 45, 49, 54) and whether the transcriptional and posttranscriptional components could be cell type specific. In HTB-17 cells, TAT transactivated the HIV-1 LTR to a level fivefold higher than did CMV IE (i.e., the CMV IE/TAT ratio was 0.2). However, there were greater steady-state levels of HIV-1 transcripts with cotransfection with CMV IE than with TAT ( Fig. 2) (4) . This is strong support for the notion that in HTB-17 cells the predominant mode of transactivation of the HIV-1 LTR TAT is posttranscriptional versus a primary role in initiation and elongation. Depending on the cell type, one mode of transactivation by TAT may be predominant over the other, and thus, this difference may affect the ratio of CMV IE-to-TAT transactivation (Tables 1 and 2 ).
In summary, there are fundamental differences between cell types in the state of the transcriptional machinery, manifested in this case as differential transactivation of the HIV-1 LTR by two viral transactivators. Complete elucidation of specific mechanisms and the role of cellular factors (16, 23, 24, 30, 34, 55, 56) will require reconstitution experiments in vitro. This report provides a basis for identification of cellular factors which provide the transcriptional selectivity we have observed. Such information is vitally important for understanding of the mechanisms that regulate viral latency and pathogenesis for both HIV and CMV. The studies reported here are also relevant for investigation of interactions of heterologous viruses, since it has been demonstrated that HIV and CMV can coinfect the same cell within a patient with AIDS (36) . Given the great variation in the abilities of these two viral transactivators (HIV-1 TAT and CMV IE) to function within different cell types in tissue culture, the biological consequences of coinfection of a host would depend on the cell type.
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